Cinda Biological Announces 2020 Annual Results and Company Progress: Three new drugs are launched, four products are commercialized, and total revenue is 3.84 billion yuan

Business summary (2020 and 2021 to present)

Three new drugs are launched, four commercial products, and product revenue in 2020 will reach 2.

• Following the official approval of Daboshu® in December 2018, the company ushered in the approval of three new drug products for the market in 2020
  
  

  The company is developing 23 high-value clinical pipelines around the world, of which 4 have been approved for marketing, 5 are in registration or key clinical stages, and 14 are in different stages of clinical phase I or phase II

  
  

  Five product pipelines are in registration or key clinical stages

  In addition to the four listed products, five other products of the company are in the registration or critical clinical stage in 2020 and are expected to be launched in the next few years, including:

  • IBI-310 (CTLA-4 monoclonal antibody)
  • IBI-375 (FGFR TKI)
  • IBI-376 (PI3Kδ TKI)
  • IBI-306 (PCSK9 monoclonal antibody)
  • IBI-326 (BCMA CAR-T)

  Comprehensive deployment of tumor pipelines, leading progress in a variety of high-potential IO targets

  In addition to the leading product PD-1 inhibitor Daboshu®, a number of high-potential tumor immunity pipelines are progressing rapidly in 2020:

  • CD47 field: The company deploys three differentiated varieties, of which IBI-188 is the potential best-in-class CD47 monoclonal antibody.
    
    

    The non-tumor pipeline has unique characteristics, covering autoimmunity, metabolism, cardiovascular and ophthalmology

    
    
    • IBI-362 (OXM3): A phase 1b study for the treatment of obese subjects and diabetic patients has been carried out, showing excellent blood sugar and weight reduction effects; a phase 2 clinical study is planned to be carried out in 2021
      
      

      From 2020 and 2021 to present, the company has reached a series of strategic cooperation with domestic and foreign partners, including:

      • In August 2020, the strategic expansion licensing agreement with Eli Lilly regarding the exclusive rights of Daboshu® outside China is a milestone in introducing the company's innovative product strategy into the international market
        
        
        • The company's team has expanded from approximately 2,000 employees at the end of 2019 to 3,200 employees at the end of 2020
          
          
          • In 2020, the company's total production capacity will be successfully expanded from 5,000 liters to 24,000 liters to meet the production needs of commercialized products and clinical stage drug candidates in research products
            
            
            • In 2020, the mark "B" was successfully removed from the company's share name
              
              
              • Realized total revenue of RMB 3.
                84 billion, a year-on-year increase of 266.
                9%
                .
                Mainly due to the strong increase in product revenue over the same period and the increase in license fees and service revenue during the reporting period
                .
                
              • Realized product revenue of RMB 2.
                37 billion, a year-on-year increase of 133.
                0%
                .
                Mainly due to the strong year-on-year growth of the leading product Daboshu and the revenue contributed by the three newly approved antibody drugs in the second half of 2020
                .
                
              • R&D investment was RMB 1.
                85 billion, a year-on-year increase of 43.
                0%
                .
                The company's R&D investment is mainly used for the development of pipeline products in the later development stage and the global development of priority products under research
                .
                
              • The net loss was RMB 1.
                0 billion, a year-on-year decrease of 42.
                0%
                .
                This was mainly due to the growth in product sales and licensing fee income during the reporting period
                .